# Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma

> **NCT05053386** · NA · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 186 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Idarubicin Hydrochloride for Injection
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT05053386
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10
- **Primary completion:** 2022-10
- **Final completion:** 2023-04
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05053386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05053386, "Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05053386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*